Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes
Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospecti...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/7984576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467882363158528 |
|---|---|
| author | Eduardo A. Novais Mauricio Maia Paulo Augusto de Arruda Mello Filho João Rafael de Oliveira Dias José Maurício B. B. Garcia Gabriel C. de Andrade Ricardo N. Louzada Marcos Ávila André Maia J. Fernando Arevalo Lihteh Wu Maria Berrocal Emmerson Badaró Michel Farah |
| author_facet | Eduardo A. Novais Mauricio Maia Paulo Augusto de Arruda Mello Filho João Rafael de Oliveira Dias José Maurício B. B. Garcia Gabriel C. de Andrade Ricardo N. Louzada Marcos Ávila André Maia J. Fernando Arevalo Lihteh Wu Maria Berrocal Emmerson Badaró Michel Farah |
| author_sort | Eduardo A. Novais |
| collection | DOAJ |
| description | Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (P<0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (P<0.001) 12 months after one (P=0.001), two (P=0.041), and three (P<0.001) implants but not four implants (P=0.068). The mean baseline CRT decreased significantly (P<0.001) from 463 to 254 microns after 12 months with one (P<0.001), two (P=0.002), and three (P=0.001) implants but not with four implants (P=0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%). Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes. |
| format | Article |
| id | doaj-art-e6a14685f23d4e5dab7ea322818101ab |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-e6a14685f23d4e5dab7ea322818101ab2025-08-20T03:26:00ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/79845767984576Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized EyesEduardo A. Novais0Mauricio Maia1Paulo Augusto de Arruda Mello Filho2João Rafael de Oliveira Dias3José Maurício B. B. Garcia4Gabriel C. de Andrade5Ricardo N. Louzada6Marcos Ávila7André Maia8J. Fernando Arevalo9Lihteh Wu10Maria Berrocal11Emmerson Badaró12Michel Farah13Department of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilFederal University of Goiás, Goiânia, GO, BrazilDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilFederal University of Goiás, Goiânia, GO, BrazilFederal University of Goiás, Goiânia, GO, BrazilDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilWilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USAAsociados de Macula Vitreo y Retina de Costa Rica, San Jose, Costa RicaUniversity of Puerto Rico, San Juan, PR, USADepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, SP, BrazilPurpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (P<0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (P<0.001) 12 months after one (P=0.001), two (P=0.041), and three (P<0.001) implants but not four implants (P=0.068). The mean baseline CRT decreased significantly (P<0.001) from 463 to 254 microns after 12 months with one (P<0.001), two (P=0.002), and three (P=0.001) implants but not with four implants (P=0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%). Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.http://dx.doi.org/10.1155/2016/7984576 |
| spellingShingle | Eduardo A. Novais Mauricio Maia Paulo Augusto de Arruda Mello Filho João Rafael de Oliveira Dias José Maurício B. B. Garcia Gabriel C. de Andrade Ricardo N. Louzada Marcos Ávila André Maia J. Fernando Arevalo Lihteh Wu Maria Berrocal Emmerson Badaró Michel Farah Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes Journal of Ophthalmology |
| title | Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes |
| title_full | Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes |
| title_fullStr | Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes |
| title_full_unstemmed | Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes |
| title_short | Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes |
| title_sort | twelve month follow up of dexamethasone implants for macular edema from various diseases in vitrectomized and nonvitrectomized eyes |
| url | http://dx.doi.org/10.1155/2016/7984576 |
| work_keys_str_mv | AT eduardoanovais twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT mauriciomaia twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT pauloaugustodearrudamellofilho twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT joaorafaeldeoliveiradias twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT josemauriciobbgarcia twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT gabrielcdeandrade twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT ricardonlouzada twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT marcosavila twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT andremaia twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT jfernandoarevalo twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT lihtehwu twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT mariaberrocal twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT emmersonbadaro twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes AT michelfarah twelvemonthfollowupofdexamethasoneimplantsformacularedemafromvariousdiseasesinvitrectomizedandnonvitrectomizedeyes |